| Description |
Currently there have been seven drugs approved for the chronic treatment of pulmonary arterial hypertension (PAH). Yet, because of the use of similar trial design and endpoints, questions remain about the longterm benefits, effects on survival, and mechanism of action of these agents, as well as the appropriate trial design. Join regulatory, industry, and academic leaders as they debate the uncertainties around the approved treatments for PAH, alternative clinical trial designs for future studies that better address the unanswered questions from the existing trials, and limitations in performing clinical trials in patients with PAH.
|
|
